Postrural Ortostatik Taşikardi Sendromu
Özet
Postural ortastatik taşikardi sendromu (POTS), kronik ortostatik intoleransın bir formu olup özellikle çocuk ve adölesanlarda sık görülür. Dik pozisyona geçildiğinde ortaya çıkan çarpıntı, baş dönmesi, yorgunluk ve egzersiz intoleransı gibi semptomlarla karakterizedir. Patofizyolojisinde otonomik dengesizlik rol oynar ve nöropatik, hipovolemik veya hiperadrenerjik gibi farklı alt gruplara ayrılır. Tedavide öncelik yaşam tarzı değişiklikleri ve tuz/su takviyesiyken, dirençli vakalarda çeşitli farmakolojik seçenekler değerlendirilir.
Postural Orthostatic Tachycardia Syndrome (POTS) is a chronic form of orthostatic intolerance that frequently affects children and adolescents. It is characterized by symptoms like palpitations, dizziness, fatigue, and exercise intolerance when transitioning to an upright position. The pathophysiology involves autonomic dysfunction, categorized into various subtypes such as neuropathic, hypovolemic, or hyperadrenergic. Management primarily focuses on lifestyle modifications, including increased salt and fluid intake, with pharmacological treatments reserved for refractory cases.
Referanslar
Stewart JM. Orthostatic intolerance in pediatrics. J Pediatr. 2002;140(4):404–11.
Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome. Neurology [Internet]. 1993 Jan 1;43(1 Part 1):132 LP – 132.
Stewart JM, Boris JR, Chelimsky G, et al. Pediatric disorders of orthostatic intolerance. Pediatrics. 2018;141(1).
Tanaka H, Fujita Y, Takenaka Y, et al. Japanese clinical guidelines for juvenile orthostatic dysregulation version 1. Pediatr Int. 2009;51(1):169–79.
Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc. 2002;77(6):531–7.
Bagai K, Song Y, Ling JF, et al. Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med. 2011;7(2):204–10.
Huh TE, Yeom JS, Kim YS, et al. Orthostatic symptoms does not always manifest during tilt-table test in pediatric postural orthostatic tachycardia syndrome patients. Korean J Pediatr. 2013;56(1):32–6.
Chouksey D, Rathi P, Sodani A, Jain R, Ishar HS. Postural orthostatic tachycardia syndrome in patients of orthostatic intolerance symptoms: an ambispective study. AIMS Neurosci. 2020;8(1):74–85.
Lee H, Low PA, Kim HA. Patients with Orthostatic Intolerance: Relationship to Autonomic Function Tests results and Reproducibility of Symptoms on Tilt. Sci Rep [Internet]. 2017;7(1):1–6.
Ives CT, Kimpinski K. Higher postural heart rate increments on head-up tilt correlate with younger age but not orthostatic symptoms. J Appl Physiol. 2013;115(4):525–8.
Hasan B, Almasri J, Marwa B, Klaas KM, Fischer PR. Treatment of Postural Orthostatic Tachycardia Syndrome With Medication: A Systematic Review. J Child Neurol. 2020;35(14):1004–16.
Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS): Clinical review. J Cardiovasc Electrophysiol. 2009;20(3):352–8.
Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome – insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286(4):438–48.
Li JW, Zhang QY, Hao HJ, Jin HF, Du JB. Clinical features and management of postural tachycardia syndrome in children: A single-center experience. Chin Med J (Engl). 2014;127(21):3684–9.
Boris JR, Bernadzikowski T. Demographics of a large paediatric Postural Orthostatic Tachycardia Syndrome Program. Cardiol Young. 2018;28(5):668–74.
Staples A, Thompson NR, Moodley M. Pediatric-Onset Postural Orthostatic Tachycardia Syndrome in a Single Tertiary Care Center. J Child Neurol. 2020;35(8):526–35.
Chelimsky G, Kovacic K, Nugent M, Mueller A, Simpson P, Chelimsky TC. Comorbid conditions do not differ in children and young adults with functional disorders with or without postural tachycardia syndrome. J Pediatr [Internet]. 2015;167(1):120–4.
Bhatia R, Kizilbash SJ, Ahrens SP, et al. Outcomes of adolescent-onset postural orthostatic tachycardia syndrome. J Pediatr [Internet]. 2016;173:149–53.
Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci. 1999 Feb;317(2):75–7.
Zadourian A, Doherty TA, Swiatkiewicz I, Taub PR. Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management. Drugs [Internet]. 2018;78(10):983–94.
Ojha A, Chelimsky TC, Chelimsky G. Comorbidities in pediatric patients with postural orthostatic tachycardia syndrome. J Pediatr [Internet]. 2011;158(1):20–3.
Bhatia R, Kizilbash SJ, Ahrens SP, et al. Outcomes of adolescent-onset postural orthostatic tachycardia syndrome. J Pediatr [Internet]. 2016;173:149–53.
Raj V, Haman KL, Raj SR, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry. 2009;80(3):339–44.
Owens AP, Low DA, Critchley HD, Mathias CJ. Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope. Auton Neurosci Basic Clin [Internet]. 2018;212(January):42–7.
Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet Part C Semin Med Genet. 2017;175(1):148–57.
Henderson FC, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers–Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175(1):195–211.
Wells R, Spurrier AJ, Linz D, et al. Postural tachycardia syndrome: Current perspectives. Vasc Health Risk Manag. 2018;14:1–11.
Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Hear Rhythm [Internet]. 2015;12(6):e41–63.
Singer W, Spies JM, McArthur J, et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology. 2004;62(4):612–8.
Peltier AC, Garland E, Raj SR, et al. Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res. 2010;20(2):93–9.
El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart. 1996;75(2):134–40.
Li J, Liao Y, Du J, Zhang Q. [Relationship between 24-hour urinary sodium and renin-angiotensin-aldosterone system in children with postural tachycardia syndrome]. Zhonghua Yi Xue Za Zhi. 2015 Sep;95(36):2928–32.
Zhang Q, Xu B, Du J. Update of Individualized Treatment Strategies for Postural Orthostatic Tachycardia Syndrome in Children. Vol. 11, Frontiers in Neurology. 2020.
Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience. Cardiol J. 2011;18(5):527–31.
Zhang Q, Chen X, Li J, Du J. Clinical features of hyperadrenergic postural tachycardia syndrome in children. Pediatr Int. 2014;56(6):813–6.
Garland EM, Celedonio JE, Raj SR. Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance. Curr Neurol Neurosci Rep. 2015;15(9).
Lambert E, Eikelis N, Esler M, et al. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 2008;1(2):103–9.
Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P. Cardiovascular autonomic dysfunction in Ehlers–Danlos syndrome—Hypermobile type. Am J Med Genet Part C Semin Med Genet. 2017;175(1):168–74.
Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos Syndrome and Postural Tachycardia Syndrome: A relationship study. J Neurol Sci [Internet]. 2014;340(1–2):99–102.
Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385–90.
Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace. 2017;19(7):1211–9.
Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci Basic Clin [Internet]. 2018;215(March):28–36.
Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci Basic Clin. 2018;215(March):20–7.
Miglis MG, Muppidi S, Feakins C, Fong L, Prieto T, Jaradeh S. Sleep disorders in patients with postural tachycardia syndrome. Clin Auton Res. 2016;26(1):67–73.
Fortunato JE, Shaltout HA, Larkin MM, Rowe PC, Diz DI, Koch KL. Fludrocortisone improves nausea in children with orthostatic intolerance (OI). Clin Auton Res. 2011;21(6):419–23.
Coffin ST, Black BK, Biaggioni I, et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Hear Rhythm [Internet]. 2012;9(9):1484–90.
Grubb B. Desmopressin In The Treatment of Postural Orthostatic Tachycardia. J Innov Card Rhythm Manag. 2015;6(12):2222–6.
Robson WL, Leung AK. Side effects and complications of treatment with desmopressin for enuresis. J Natl Med Assoc. 1994;86(10):775–8.
Arnold AC, Okamoto LE, Diedrich A, et al. Low-dose propranolol and exercise capacity in postural tachycardia syndrome a randomized study. Neurology. 2013;80(21):1927–33.
Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58(2):167–75.
Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome less is more. Circulation. 2009;120(9):725–34.
Yozgat Y, Temur HO, Coban S, et al. Short-term efficacy of ORS formulation and propranolol regimen in children with POTS. Arch Pediatr [Internet]. 2020;27(6):328–32.
Delle Donne G, Rosés Noguer F, Till J, Salukhe T, Prasad SK, Daubeney PEF. Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children. Am J Cardiovasc Drugs. 2018;18(1):59–63.
McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13(3):427–30.
Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. PACE - Pacing Clin Electrophysiol. 2017;40(11):1242–5.
Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: A single-center experience. PACE - Pacing Clin Electrophysiol. 2011;34(6):750–5.
Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111(21):2734–40.
Filler G, Gow RM, Nadarajaha R, et al. Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome. Pediatrics. 2006;118(5).
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997 Apr;277(13):1046–51.
Lai CC, Fischer PR, Brands CK, et al. Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and β-blockers. PACE - Pacing Clin Electrophysiol. 2009;32(2):234–8.
Yang J, Zhao J, Du S, et al. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride. J Pediatr [Internet]. 2013;163(4):1169-1173.e2.
Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of octreotide in the treatment of refractory orthostatic intolerance. Am J Ther. 2012;19(1):7–10.
Hoeldtke RD, Bryner KD, Hoeldtke ME, Hobbs G. Treatment of postural tachycardia syndrome: A comparison of octreotide and midodrine. Clin Auton Res. 2006;16(6):390–5.
Kpaeyeh J, Mar PL, Raj V, et al. Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2014;34(6):738–41.
Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. Am J Ther. 2012;19(1):2–6.
Gaffney FA, Lane LB, Pettinger W, Blomqvist CG. Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest. 1983;83(Suppl. 2):436–8.
